Navigation Links
Yeast unravels effects of chemotherapy drugs
Date:9/9/2009

Until now, the mode of action of nitrogen-containing bisphosphonate (N-BP) cancer drugs, used to relieve bone pain and to prevent skeletal complications in bone metastasis, has been almost entirely unknown. Researchers writing in BioMed Central's open access journal Genome Biology have used 'barcoded' yeast mutants to identify new biological processes involved in the cellular response to N-BPs, opening up opportunities for the development of new anticancer drugs.

Daniela Delneri, from the University of Manchester, UK, worked with Gianluca Tell and an Italian team of researchers to carry out the experiments. Delneri said, "We discovered two novel biological processes involved in the cytotoxic effects of the N-BPs, DNA damage and microtubule assembly, and, thanks to the novel 'barcode' approach, these could be linked directly to the responsible genes, DBF4 and TBCB."

The researchers used a collection of thousands of yeast mutants, each identified by a unique molecular barcode. By evaluating which yeasts grew best when exposed to N-BPs, they were able to identify potential drug targets and gain insight into the molecular changes occurring in cells exposed to such drugs. Speaking about the results, Delneri said, "Neither DBF4 nor TBCB have been described before as N-BP targets, and these findings may open up new opportunities for the development of new compounds with antitumor activity".


'/>"/>

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-203-192-2165
BioMed Central
Source:Eurekalert

Page: 1

Related medicine news :

1. Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
2. Study Links Sugar Production in Yeast Cells to Longevity
3. How yeast is helping us to understand Parkinsons Disease
4. Yeast mimics severity of mutations leading to fatal childhood illness
5. Genetic Approach Boosts Yeast Infection Treatment
6. Fish oil and red yeast rice studied for lowering blood cholesterol
7. New research on mutation in yeast can enhance understanding of human diseases
8. Chinese Red Yeast Rice May Prevent Heart Attack
9. Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
10. Yeast gives rise to new concept: cell fuel is brains behind division
11. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , ... August 03, 2015 , ... ... agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions ... health care costs. , Annually, more than 8.6 million adverse drug events ...
(Date:8/3/2015)... FL (PRWEB) , ... August ... ... most-visited bodybuilding and fitness site and the largest online retailer of nutritional ... Awards. BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. ... lifecycle management solution, as well as announced the date of its next major ... ease of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical ... on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New ... may be accessed via the investor relations section of the Company’s website. , About ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration ... is similar to deoxycholic acid, which occurs naturally in the body and helps absorb ... treat this area of the body. These are invasive procedures and very expensive for ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Exposure to environmental levels of the industrial chemical bisphenol A, ... long-lasting harm to testicular function, according to a new study ... The Endocrine Society,s 92nd Annual Meeting in San Diego. ... after exposure to BPA levels that are lower than what ...
... revelation that the chair of the board of Canada,s ... until April 2010 sends an unfortunate message to the ... states an editorial http://www.cmaj.ca/cgi/doi/10.1503/cmaj.100850 in CMAJ ( ... no place for the tobacco industry on the development ...
... , ... rank search results higher when there is promoter activity behind the website. , ... (PRWEB) June 21, 2010 -- The Active ... called Active Search Results Page Ranking Technology (ASR Ranking). , , ,ASR Ranking allows ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... performance for the year ending March 31, 2010 in spite of the economic turmoil’s impact ... the second half of 2010 compared with the same period last year. , ... Auckland, New Zealand (Vocus) June 21, 2010 ...
... The ... 33 times greater than that reported for our accredited ambulatory surgery centers. , ... (PRWEB) June 18, 2010 ... Michael Jhung et al (JAMA 2010;303(22):2273 - 2279) correctly places emphasis on the importance ...
Cached Medicine News:Health News:Early-life exposure to BPA may affect testis function in adulthood 2Health News:CMAJ calls for resignation of IDRC chair Barbara McDougall 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 3Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 4Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 5Health News:Infection Rate in Accredited Ambulatory Facilities is Lower than in Hospitals 2
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the developer ... metabolic diseases and other gastrointestinal disorders, today announced that ... the Board of Directors, effective July 31, 2015.  Ms. ... the 2018 annual meeting or until her successor is ... in an executive capacity in the healthcare industry for ...
(Date:8/2/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... discover and develop antisense therapies for cardiovascular, metabolic ... a broad existing relationship between the two companies ... areas using novel RNA-targeted treatments. It also enables ... technology to diseases of the kidney. ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4
... statins for only five weeks at,400 mg/week lowered ... with similarly favorable effects on other,atherogenic lipids, NEW ... Isis Pharmaceuticals, Inc. announced new,results from its Phase ... presented today at the of Cardiology,Annual Scientific Session ...
... Only Illinois Site in Trial , CHICAGO, March ... adult stem cell therapy, Provacel™,experienced a lower number ... significant improvements in heart, lung and,global function compared ... Phase I study data presented at the American ...
Cached Medicine Technology:Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 2Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: